{"id":"https://genegraph.clinicalgenome.org/r/9d7ad9bc-1435-44a1-8c45-9c8599c29204v3.0","type":"EvidenceStrengthAssertion","dc:description":"The relationship between *VKORC1* and combined deficiency of vitamin K-dependent clotting factors, type 2 (VKCFD2), an autosomal recessive disorder, was evaluated using the ClinGen Clinical Validity Framework as of July, 2025. *VKORC1* encodes the catalytic subunit of the vitamin K epoxide reductase complex, which is involved in the reduction of inactive vitamin K 2,3-epoxide to active vitamin K (RefSeq, Aug 2015). Patients with VKCFD2 present with severe bleeding manifestations and absent or reduced activity of vitamin K-dependent clotting factors.  The condition, VKCFD, type 1 is caused by mutations in the GGCX gene.\n\n*VKORC1* was first reported in relation to autosomal recessive VKCFD2 in 2004 (Rost et al, PMID: 14765194). Only one missense variant has been reported in this gene in relation to VKCFD2. While several polymorphisms in *VKORC1* have been reported in association with variability in response to vitamin K antagonists (VKA), this does not constitute a clinical disease entity. These variants have not been included in this curation. Evidence supporting this gene-disease relationship includes case-level data and experimental data. \n   \nSummary of Case Level Data (3 points):\nAt least 3 patients from 3 families in 5 publications have been reported with the same homozygous missense variant, Arg98Trp, which is considered a mutational hotspot (PMID: 12704386). The variant segregated in 5 additional family members. The mechanism is expected to be biallelic loss of function. \n  \nSummary of experimental data (3.5 points):\nThis gene-disease association is supported by a knock-out mouse model that recapitulates the bleeding phenotype seen in human patients, however, it is more severe and lethal (PMID: 19492146). *VKORC1* function is not completely understood, but it localizes to the ER and its mislocalization due to the Arg98Trp variant is reported to be the mechanism of disease in VKCFD2 (PMID: 14765194, 24963046). Wild-type *VKORC1* restores VKOR activity in cell culture (PMID: 14765194).\n  \nIn summary, the level of evidence to support the gene-disease relationship of *VKORC1* and autosomal recessive combined deficiency of vitamin K-dependent clotting factors, type 2, is moderate. While more evidence is needed to establish this relationship definitively, no convincing contradictory evidence has emerged.\n\nThis gene-disease pair was originally approved by the HT GCEP on 06/24/2020. It was reevaluated on 04/03/2023 and 07/29/2025. As a result of these reevaluations no new evidence was identified and the classification remained at Moderate (SOP Version 11).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/9d7ad9bc-1435-44a1-8c45-9c8599c29204","GCISnapshot":"https://genegraph.clinicalgenome.org/r/84145ffe-9835-4a3a-a2ae-6d0c6bd34007","calculatedEvidenceStrength":"Moderate","changes":[{"id":"cg:sopChange"},{"id":"cg:summaryChange"}],"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/84145ffe-9835-4a3a-a2ae-6d0c6bd34007_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10028","date":"2025-09-03T12:40:45.191Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/84145ffe-9835-4a3a-a2ae-6d0c6bd34007_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10028","date":"2025-09-03T16:00:00.000Z","role":"Approver"}],"curationReasons":["RecurationTiming"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/84145ffe-9835-4a3a-a2ae-6d0c6bd34007_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6e9d2a07-3e5f-45c2-9bdd-953a151401f2_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6e9d2a07-3e5f-45c2-9bdd-953a151401f2","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14765194","rdfs:label":"Rost_Family B - Proband (B3)","allele":{"id":"https://genegraph.clinicalgenome.org/r/478f05a7-1f4f-41f1-b14c-0636e69e0602","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_024006.6(VKORC1):c.292C>T (p.Arg98Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA115411"}},"detectionMethod":"All 3 exons and exon-intron boundaries were amplified by PCR and directly sequenced.","firstTestingMethod":"PCR","phenotypes":["obo:HP_0001510","obo:HP_0012541","obo:HP_0011858","obo:HP_0005543","obo:HP_0008151","obo:HP_0008169","obo:HP_0002313","obo:HP_0001342","obo:HP_0008321","obo:HP_0001256","obo:HP_0000238","obo:HP_0001250"],"previousTesting":true,"previousTestingDescription":"All 15 exons and flanking regions of the GGCX gene were amplified and sequenced, no mutations were detected. Haplotype analyses confirmed no association to the gene. (From PMID: 11154138) FII:C = 45 U/dl; FVII:C = 29 U/dl; FIX:C = 55 U/dl; FX:C = 33 U/dl; PC:C = 60 U/dl (reference for all = 70-130). Basal serum concentration of Vit K = 0.7 ng/ml and Vit K epoxide <0.05 ng/ml. After oral substituion of 10mg Vit K, serum Vit K = 490.4 ng/ml and Vit K epoxide = 66.2 ng/ml. Vit K/Vit K epoxide = 7.4","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/99f92b11-2e44-418c-b6c6-412dec248716_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14765194","allele":{"id":"https://genegraph.clinicalgenome.org/r/478f05a7-1f4f-41f1-b14c-0636e69e0602"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/99f92b11-2e44-418c-b6c6-412dec248716","type":"EvidenceLine","dc:description":"The authors suggest that this variant could be a hotspot as it occurs at a CpG dinucleotide and since the haplotypes of the two families reported are different. The variant is reported at a frequency of 0.0001256 (16/127412 non-Finnish European alleles) with no homozygotes.","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/99f92b11-2e44-418c-b6c6-412dec248716_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/99f92b11-2e44-418c-b6c6-412dec248716_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"PMID: 24963046 provides functional evidence to show that this missense variant disrupts a di-arginine ER-retention motif and results in 20% ER colocalization only. ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/cd746911-7e6e-42a8-8f9d-eac6be72f2f2_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cd746911-7e6e-42a8-8f9d-eac6be72f2f2","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18315553","rdfs:label":"Marchetti_Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":34,"allele":{"id":"https://genegraph.clinicalgenome.org/r/478f05a7-1f4f-41f1-b14c-0636e69e0602"},"detectionMethod":"All exons and intron-exon boundaries of VKORC1 were amplified and sequenced.","firstTestingMethod":"PCR","phenotypes":["obo:HP_0008169","obo:HP_0011854","obo:HP_0005543","obo:HP_0000225","obo:HP_0000132","obo:HP_0004406","obo:HP_0008321","obo:HP_0011858","obo:HP_0004855","obo:HP_0002573","obo:HP_0000138","obo:HP_0008151","obo:HP_0011891","obo:HP_0000939"],"previousTesting":true,"previousTestingDescription":"Scanning of all exons and intron-exon boundaries of GGCX gene revealed two intronic and one synonymous variants. Baseline coagulation factor activity leveles: APTT = 33s; PT = 107s; FVII:C = 14%; FIX:C = 8%; FX:C = 8%; FII:C = 26s; PC:C = 36%; PS:C = 27%","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/6ff76997-7d17-45ff-9427-cf4e784f4115_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18315553","allele":{"id":"https://genegraph.clinicalgenome.org/r/478f05a7-1f4f-41f1-b14c-0636e69e0602"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/6ff76997-7d17-45ff-9427-cf4e784f4115","type":"EvidenceLine","dc:description":"The proband was homozygous for the recurring missense variant, Arg98Trp but is also also homozygous for the -323ins10 variant in the F7 gene, which is a polymorphism associated with reduction in FVII levels. ","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6ff76997-7d17-45ff-9427-cf4e784f4115_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/6ff76997-7d17-45ff-9427-cf4e784f4115_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"PMID: 24963046 provides functional evidence to show that this missense variant disrupts a di-arginine ER-retention motif and results in 20% ER colocalization only. ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/84145ffe-9835-4a3a-a2ae-6d0c6bd34007_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c8449406-6b6c-4614-bfe9-4ac7493cd969_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14765194","rdfs:label":"Rost_Family A","family":{"id":"https://genegraph.clinicalgenome.org/r/c8449406-6b6c-4614-bfe9-4ac7493cd969","type":"Family","rdfs:label":"Rost_Family A","member":{"id":"https://genegraph.clinicalgenome.org/r/cb79b23c-a8ae-4131-b619-9ed9f2885959","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14765194","rdfs:label":"Rost_Family A - Proband (A5)","allele":{"id":"https://genegraph.clinicalgenome.org/r/478f05a7-1f4f-41f1-b14c-0636e69e0602"},"detectionMethod":"All 3 exons and exon-intron boundaries were amplified by PCR and directly sequenced.","firstTestingMethod":"PCR","phenotypeFreeText":"Proband recieved a ventriculoperitoneal shunt after the occurrence of intracerebral bleeding.","phenotypes":["obo:HP_0001892","obo:HP_0008151","obo:HP_0005543","obo:HP_0008169","obo:HP_0011858","obo:HP_0001342","obo:HP_0008321"],"previousTesting":true,"previousTestingDescription":"All 15 exons and flanking regions of the GGCX gene were amplified and sequenced, no mutations were detected. Haplotype analyses confirmed no association to the gene. (From PMID: 11154138) FII:C = 40 U/dl; FVII:C = 20 U/dl; FIX:C = 52 U/dl; FX:C = 24 U/dl; PC:C = 61 U/dl (reference for all = 70-130). Basal serum concentration of Vit K = 0.4 ng/ml and Vit K epoxide <0.05 ng/ml. After oral substituion of 10mg Vit K, serum Vit K = 84.6 ng/ml and Vit K epoxide =19.5 ng/ml. Vit K/Vit K epoxide = 4.3","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/41d6ddc4-faa7-4946-8979-ccfa88a13d3c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14765194","allele":{"id":"https://genegraph.clinicalgenome.org/r/478f05a7-1f4f-41f1-b14c-0636e69e0602"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}}},"meetsInclusionCriteria":true,"phenotypeNegativeAlleleNegative":3,"phenotypePositiveAllelePositive":5,"phenotypes":["obo:HP_0008151","obo:HP_0008169","obo:HP_0008321","obo:HP_0011858","obo:HP_0005543"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/cb79b23c-a8ae-4131-b619-9ed9f2885959"},"publishedLodScore":2.78,"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/f610f38e-db09-4ca9-b834-1233a9ec74de_proband_segregation","type":"FamilyCosegregation","dc:description":"Per Gene curation SOP v7, a minimum of 3 affected individuals required to count segregation points.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14765194","rdfs:label":"Rost_Family B","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/f610f38e-db09-4ca9-b834-1233a9ec74de","type":"Family","rdfs:label":"Rost_Family B","member":{"id":"https://genegraph.clinicalgenome.org/r/6e9d2a07-3e5f-45c2-9bdd-953a151401f2"}},"meetsInclusionCriteria":false,"phenotypeNegativeAlleleNegative":0,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0008151","obo:HP_0005543","obo:HP_0008169","obo:HP_0008321","obo:HP_0011858"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/6e9d2a07-3e5f-45c2-9bdd-953a151401f2"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/cb79b23c-a8ae-4131-b619-9ed9f2885959_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cb79b23c-a8ae-4131-b619-9ed9f2885959"},{"id":"https://genegraph.clinicalgenome.org/r/41d6ddc4-faa7-4946-8979-ccfa88a13d3c","type":"EvidenceLine","dc:description":"The authors suggest that this variant could be a hotspot as it occurs at a CpG dinucleotide and since the haplotypes of the two families reported are different. The variant is reported at a frequency of 0.0001256 (16/127412 non-Finnish European alleles) with no homozygotes. ","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/41d6ddc4-faa7-4946-8979-ccfa88a13d3c_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/41d6ddc4-faa7-4946-8979-ccfa88a13d3c_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"PMID: 24963046 provides functional evidence to show that this missense variant disrupts a di-arginine ER-retention motif and results in 20% ER colocalization only. ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/84145ffe-9835-4a3a-a2ae-6d0c6bd34007_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/84145ffe-9835-4a3a-a2ae-6d0c6bd34007_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a3724d78-2a95-42e3-b8b9-58ed1617dacf","type":"EvidenceLine","dc:description":"Mislocalization from the ER has been shown to be the mechanism of disease due to the missense variant, Arg98Trp, the only reported mutation in this disease. (This may also be scored as evidence for biochemical functions consistent with phenotype, but was considered appropriate in expression evidence.) Therefore, this evidence is scored default points.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a7dfcf2e-fe64-4e2d-b9a2-5780dadfc71b","type":"Finding","dc:description":"VKORC1 was found to be widely expressed, but the highest expression was noted in the liver. Specifically, VKORC1 was found to localize in the ER - constructs expressing GFP- and Myc-tagged VKORC1 fusion proteins were transfected to COS-7 cells for immunofluorescence experiments, with ER-specific calnexin used as control.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14765194","rdfs:label":"Rost_VKORC1 ER localization","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/84145ffe-9835-4a3a-a2ae-6d0c6bd34007_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b6e72864-865d-4a0c-ab88-05d5e63841f4","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/16e0eea2-6bb1-4ad5-8cce-05347f68a199","type":"Finding","dc:description":"Untransfected and mock-transfected cells showed basal activity of 1.49% and 0.96%, which was sensitive to warfarin. Overexpression of wild-type VKORC1 resulted in marked stimulation of VKOR activity (20.29%), while recombinant Arg98Trp expression only slightly increased activity (1.81%).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14765194","rdfs:label":"Rost_Rescue in cell culture","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityCellCultureRescueCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/5c4873d0-03aa-414e-8809-7a47f59e4853","type":"EvidenceLine","dc:description":"The mouse model recapitulates with greater severity, the bleeding phenotype observed in humans. This underscores the fact that this gene may be intolerant to loss of function and only one missense change is reported to cause the bleeding phenotype in humans.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2a3c507c-ac30-4f17-8126-71654c5a4de0","type":"Finding","dc:description":"Absent VKORC1 mRNA expression was confirmed in liver preparations of mice at day P8 using qPCR. VKORC1-/- mice were born at expected Mendelian ratio, appeared normal but died between day P1 and P20. 50% of the offspring died between P6 and P9. Subdural bleeding, intracerebral and intramuscular bleeding were evident in 75% of dead animals. Rescue experiment with daily oral administration of 30-50 Î¼g vitamin K to mutant neonates led to survival rate of knock-out ice similar to heterozygous and WT mice. When vitamin K supplementation was stopped after 3 weeks, all knock-out mice died within 7 days and exhibited subdural hemorrhage and subcutaneous bleeding. % activities of FII, FVII, FIX, and FX improved with vitamin K substitution, but dropped near zero when supplementation was stopped. Significant reduction in the length of long bones of both P8 VKORC1-/- and VKORC1-/+ mice were seen in comparison to WT mice.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19492146","rdfs:label":"Spohn_Mouse","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":3}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":3.5}],"evidenceStrength":"Moderate","sequence":11463,"specifiedBy":"GeneValidityCriteria11","strengthScore":6.5,"subject":{"id":"https://genegraph.clinicalgenome.org/r/kPExN_XJ39M","type":"GeneValidityProposition","disease":"obo:MONDO_0011837","gene":"hgnc:23663","modeOfInheritance":"obo:HP_0000007"},"version":"3.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_84145ffe-9835-4a3a-a2ae-6d0c6bd34007-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}